Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C38H69NO13 |
Molecular Weight | 747.9534 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 18 / 18 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC
InChI
InChIKey=AGOYDEPGAOXOCK-KCBOHYOISA-N
InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
Molecular Formula | C38H69NO13 |
Molecular Weight | 747.9534 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 18 / 18 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050662s054,050698s033,050775s002lbl.pdfCurator's Comment: description was created based on several sources, including www.ncbi.nlm.nih.gov/pubmed/10760175
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050662s054,050698s033,050775s002lbl.pdf
Curator's Comment: description was created based on several sources, including www.ncbi.nlm.nih.gov/pubmed/10760175
Clarithromycin is an antibacterial drug which is used either in combination with lansoprazole and amoxicillin (Prevpac), in combination with omeprazole and amoxicillin (Omeclamox) or alone (Biaxin) for the treatment of broad range of infections. The drug exerts its action by binding to 23s rRNA (with nucleotides in domains II and V). The binding leads to the protein synthesis inhibition and the cell death.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 |
9.5 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BIAXIN Approved UseBIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults. Launch Date1991 |
|||
Curative | BIAXIN Approved UseBIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults. Launch Date1991 |
|||
Curative | BIAXIN Approved UseBIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults. Launch Date1991 |
|||
Curative | BIAXIN Approved UseBIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults. Launch Date1991 |
|||
Curative | BIAXIN Approved UseBIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults. Launch Date1991 |
|||
Curative | BIAXIN Approved UseBIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults. Launch Date1991 |
|||
Curative | BIAXIN Approved UseBIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults. Launch Date1991 |
|||
Curative | BIAXIN Approved UseBIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults. Launch Date1991 |
|||
Curative | BIAXIN Approved UseBIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults. Launch Date1991 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.09 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17606673/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLARITHROMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.21 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17606673/ |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CLARITHROMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.45 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17606673/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLARITHROMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
26.81 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17606673/ |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CLARITHROMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17606673/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLARITHROMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17606673/ |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CLARITHROMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28.7% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17606673/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLARITHROMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17606673/ |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CLARITHROMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
500 mg 2 times / day steady, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy, 33 - 51 years Health Status: unhealthy Age Group: 33 - 51 years Sex: M+F Sources: |
Other AEs: Taste metallic, Gastrointestinal pain... Other AEs: Taste metallic (19 patients) Sources: Gastrointestinal pain (4 patients) Nausea (5 patients) Vomiting (3 patients) Diarrhea (2 patients) Headache (7 patients) |
2000 mg 2 times / day steady, oral Highest studied dose Dose: 2000 mg, 2 times / day Route: oral Route: steady Dose: 2000 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Other AEs: Abdominal pain, Diarrhea... Other AEs: Abdominal pain (7.5%) Sources: Diarrhea (9.4%) Flatulence (7.5%) Headache (7.5%) Nausea (28.3%) Rash (9.4%) Taste perversion (18.9%) Vomiting (24.5%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Taste metallic | 19 patients | 500 mg 2 times / day steady, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy, 33 - 51 years Health Status: unhealthy Age Group: 33 - 51 years Sex: M+F Sources: |
Diarrhea | 2 patients | 500 mg 2 times / day steady, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy, 33 - 51 years Health Status: unhealthy Age Group: 33 - 51 years Sex: M+F Sources: |
Vomiting | 3 patients | 500 mg 2 times / day steady, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy, 33 - 51 years Health Status: unhealthy Age Group: 33 - 51 years Sex: M+F Sources: |
Gastrointestinal pain | 4 patients | 500 mg 2 times / day steady, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy, 33 - 51 years Health Status: unhealthy Age Group: 33 - 51 years Sex: M+F Sources: |
Nausea | 5 patients | 500 mg 2 times / day steady, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy, 33 - 51 years Health Status: unhealthy Age Group: 33 - 51 years Sex: M+F Sources: |
Headache | 7 patients | 500 mg 2 times / day steady, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy, 33 - 51 years Health Status: unhealthy Age Group: 33 - 51 years Sex: M+F Sources: |
Taste perversion | 18.9% | 2000 mg 2 times / day steady, oral Highest studied dose Dose: 2000 mg, 2 times / day Route: oral Route: steady Dose: 2000 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Vomiting | 24.5% | 2000 mg 2 times / day steady, oral Highest studied dose Dose: 2000 mg, 2 times / day Route: oral Route: steady Dose: 2000 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Nausea | 28.3% | 2000 mg 2 times / day steady, oral Highest studied dose Dose: 2000 mg, 2 times / day Route: oral Route: steady Dose: 2000 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Abdominal pain | 7.5% | 2000 mg 2 times / day steady, oral Highest studied dose Dose: 2000 mg, 2 times / day Route: oral Route: steady Dose: 2000 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Flatulence | 7.5% | 2000 mg 2 times / day steady, oral Highest studied dose Dose: 2000 mg, 2 times / day Route: oral Route: steady Dose: 2000 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Headache | 7.5% | 2000 mg 2 times / day steady, oral Highest studied dose Dose: 2000 mg, 2 times / day Route: oral Route: steady Dose: 2000 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Diarrhea | 9.4% | 2000 mg 2 times / day steady, oral Highest studied dose Dose: 2000 mg, 2 times / day Route: oral Route: steady Dose: 2000 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Rash | 9.4% | 2000 mg 2 times / day steady, oral Highest studied dose Dose: 2000 mg, 2 times / day Route: oral Route: steady Dose: 2000 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no | ||||
no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/15735612/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15735612/ |
no | |||
no | ||||
no | no (co-administration study) Comment: Administration of CLARITHROMYCIN had no effect on caffeine PK Sources: https://pubmed.ncbi.nlm.nih.gov/11408369/ |
|||
no | no (co-administration study) Comment: Administration of CLARITHROMYCIN had no effect on tolbutamide (CYP2C9 probe) PK Sources: https://pubmed.ncbi.nlm.nih.gov/11408369/ |
|||
no | no (co-administration study) Comment: Administration of CLARITHROMYCIN had no effect on dextromethorphan (CYP2D6 probe) PK Sources: https://pubmed.ncbi.nlm.nih.gov/11408369/ |
|||
strong | yes (co-administration study) Comment: Serious adverse reactions have been reported in patients taking larithromycin concomitantly with CYP3A4 substrates. |
|||
weak | ||||
yes [IC50 14 uM] | ||||
yes [IC50 43.5 uM] | ||||
yes [IC50 5.3 uM] | ||||
yes [IC50 59 uM] | ||||
yes [IC50 61.7 uM] | ||||
yes [IC50 8.9 uM] | yes (co-administration study) Comment: Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have been reported in post-marketing surveillance |
|||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. | 1999 Apr 16 |
|
Disseminated Mycobacterium genavense infection in a patient with acquired immunodeficiency syndrome: first case report in Taiwan. | 1999 Jan |
|
Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae. | 2001 |
|
In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria. | 2001 Apr |
|
Molecular resistance testing of Helicobacter pylori in gastric biopsies. | 2001 Apr |
|
Six cases of confluent and reticulated papillomatosis alleviated by various antibiotics. | 2001 Apr |
|
Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus. | 2001 Apr |
|
Evaluation of the immunomodulatory effects of the macrolide antibiotic, clarithromycin, in female B6C3F1 mice: a 28-day oral gavage study. | 2001 Feb |
|
[Eradication therapy of Helicobacter pylori infection]. | 2001 Feb |
|
[The history of Helicobacter pylori]. | 2001 Feb |
|
Breakthrough Streptococcus pneumoniae meningitis during clarithromycin therapy for acute otitis media. | 2001 Feb |
|
A rare case of osteomyelitis of the sternum in an adult with sickle cell disease. | 2001 Feb |
|
Mycobacterium abscessus wound infection. | 2001 Feb |
|
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? | 2001 Feb |
|
[Antimicrobial resistant test of H. pylori]. | 2001 Feb |
|
[Recent guidelines for the management of Helicobacter pylori infection]. | 2001 Feb |
|
[Prevalence and treatment of Helicobacter pylori in gastro-duodenal ulcers. An experience in Liege]. | 2001 Jan |
|
Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. | 2001 Jan |
|
Adverse reactions to rifabutin. | 2001 Jan |
|
Clarithromycin and CNS disturbances. | 2001 Mar |
|
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. | 2001 Mar |
|
Phenotypic consequences of red-white colony type variation in Mycobacterium avium. | 2001 Mar |
|
A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication. | 2001 Mar |
|
One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. | 2001 Mar |
|
What have we learned from pharmacokinetic and pharmacodynamic theories? | 2001 Mar 15 |
|
Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes. | 2001 Mar 15 |
|
[Buruli ulcer in Togo: 21 cases]. | 2001 Mar 24 |
|
Microsatellite instability at D18S61 is associated with no regression of gastric mucosa-associated lymphoid tissue lymphoma after Helicobacter pylori eradication. | 2001 Mar-Apr |
|
c-myc gene mutation in gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma. | 2001 Mar-Apr |
|
Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome. | 2001 May |
|
Prospective evaluation of the impact of amoxicillin, clarithromycin and their combination on human gastrointestinal colonization by Candida species. | 2001 May-Jun |
|
Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone. | 2001 May-Jun |
|
A multicenter study of the antimicrobial susceptibility of Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis isolated from patients with community-acquired lower respiratory tract infections in 1999 in Portugal. | 2001 Spring |
Sample Use Guides
The recommended dosages of clarithromycin tablets for the treatment of mild to moderate infections in adults are: 250 mg or 500 mg every 12 hours for 7–14 days; 500 mg every 8 or 12 hours for 10-14 days (H.pylori, in in combination with lansoprazole/amoxicillin, in combination with omeprazole/amoxicillin or omeprazole); 500 mg every 12 hours (Mycobacterial Infections).
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:12:05 GMT 2025
by
admin
on
Mon Mar 31 18:12:05 GMT 2025
|
Record UNII |
H1250JIK0A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A02BD09
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-ATC |
A02BD07
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-VATC |
QA02BD05
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
FDA ORPHAN DRUG |
770820
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-VATC |
QJ01FA09
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
NDF-RT |
N0000007529
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-VATC |
QA02BD04
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-ATC |
J01FA09
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.2
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
NDF-RT |
N0000007529
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
FDA ORPHAN DRUG |
338811
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
NDF-RT |
N0000007529
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
LIVERTOX |
NBK547886
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-ATC |
A02BD05
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-ATC |
A02BD06
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-VATC |
QA02BD06
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
NDF-RT |
N0000175935
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-VATC |
QA02BD07
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-ATC |
A02BD04
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
WHO-ATC |
A02BD11
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
||
|
NCI_THESAURUS |
C261
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m3608
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | Merck Index | ||
|
N0000190114
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | Cytochrome P450 3A Inhibitors [MoA] | ||
|
N0000182141
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | Cytochrome P450 3A4 Inhibitors [MoA] | ||
|
8055
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
Y-76
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
3732
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
CHEMBL1741
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
N0000185503
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | P-Glycoprotein Inhibitors [MoA] | ||
|
81103-11-9
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
DB01211
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
DTXSID3022829
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
C1054
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
6252
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
H1250JIK0A
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
Clarithromycin
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
1134379
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
CLARITHROMYCIN
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
758704
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
21212
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | RxNorm | ||
|
H1250JIK0A
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
100000092364
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
668
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
SUB06641MIG
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
D017291
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
84029
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
PRIMARY | |||
|
1134390
Created by
admin on Mon Mar 31 18:12:05 GMT 2025 , Edited by admin on Mon Mar 31 18:12:05 GMT 2025
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
MAJOR
Ki
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> INDUCER | |||
|
TARGET ORGANISM->INHIBITOR |
18 STRAINS; LESS THE 8 ng/mL for some strains; MIC range listed
MIC90
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
14-Clarithromycin is less active than the parent molecule.
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: RESISTANT |
|
||
Biological Half-life | PHARMACOKINETIC |
|
14-OH-CLARITHROMYCIN |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: SUSCEPTIBLE |
|
||
Tmax | PHARMACOKINETIC |
|
FORMULATION: EXTENDED RELEASE |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: RESISTANT |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: INTERMEDIATE |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: INTERMEDIATE |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: INTERMEDIATE |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: S. PYOGENES, S. PNEUMONIAE, H. PYLORI |
|
||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
FORMULATION: IMMEDIATE RELEASE |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: S. AUREUS |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: SUSCEPTIBLE |
|
||